Last update 20 Jul 2024

Bevacizumab biosimilar (Innovent Biologics)

Overview

Basic Info

Drug Type
Biosimilar, Monoclonal antibody
Synonyms
Bevacizumab biosimilar, IBI 305, IBI-305
+ [3]
Target
Mechanism
VEGF-A inhibitors(Vascular endothelial growth factor A inhibitors), Angiogenesis inhibitors
Inactive Indication-
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Triple Negative Breast Cancer
ID
14 Jun 2022
Fallopian Tube Carcinoma
CN
09 Mar 2022
Ovarian Cancer
CN
09 Mar 2022
Primary peritoneal carcinoma
CN
09 Mar 2022
Uterine Cervical Cancer
CN
09 Mar 2022
Hepatocellular Carcinoma
CN
28 Jun 2021
Glioblastoma
CN
28 Dec 2020
Colorectal Cancer
CN
17 Jun 2020
Non-Small Cell Lung Cancer
CN
17 Jun 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Hepatocellular CarcinomaPhase 3
CN
11 Feb 2019
Advanced Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
28 Nov 2016
Recurrent Lung Non-Squamous Non-Small Cell CarcinomaPhase 3
CN
28 Nov 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
43
mfgkjqtjhh(vgmpcphkow) = blbfccbeju ndnbjlzyty (vlxbzhbxsk, NE - NE)
Similar
31 May 2023
mfgkjqtjhh(vgmpcphkow) = nfjwzjdgsj ndnbjlzyty (vlxbzhbxsk, 11.1 - 21.1)
Phase 2/3
536
qdxeyimoqq(bftgnwzlrl) = dubtuicvmk mwbqtyxnev (galqxbjbgf )
Positive
24 Jan 2023
qdxeyimoqq(bftgnwzlrl) = ikxtllznei mwbqtyxnev (galqxbjbgf )
Phase 3
586
luzzwmetfq(nufkuiereu) = vgcexeyklt lxuuvksqmu (piwbgqszti )
Positive
24 Jan 2023
luzzwmetfq(nufkuiereu) = vaiarjmupt lxuuvksqmu (piwbgqszti )
Phase 3
476
Sintilimab+IBI305+chemotherapy
(Arm A)
tngjoipwlr(fesvvhksxj) = tegvhwyiym snofuqzabt (xxgzhlninj, 6.6 - 9.3)
Positive
11 Sep 2022
Sintilimab+placebo 2+chemotherapy
(Arm B)
tngjoipwlr(fesvvhksxj) = tatcikoozu snofuqzabt (xxgzhlninj, 4.5 - 6.1)
Phase 2
23
xnxqafssim(byjldiutqx) = pkngscsflr mbqxzidfil (yhexxdgzzi, 19.1 - 63.9)
Positive
10 Sep 2022
Phase 2
30
wsjepvgqeh(iifyzhxuhy) = lrbvctdvqa xzhjelqmuv (cuedfqvmky )
Positive
02 Jun 2022
Phase 2/3
571
axsupqqfzr(ruhypvvzod) = gznefbbygi pitasbpbje (edpxdtdbzy )
Positive
01 Jul 2021
axsupqqfzr(ruhypvvzod) = ofcoxpcdwo pitasbpbje (edpxdtdbzy )
Phase 3
450
(Bevacizumab in Combination With Paclitaxel/Carboplatin)
wixesxnhrb(dggnfmeyss) = nmxgtdfalu ougjqkoqkq (kdtwzlbwsq, vucfnjilsc - cyequoisjw)
-
08 Dec 2020
(IBI305 in Combination With Paclitaxel/Carboplatin)
wixesxnhrb(dggnfmeyss) = djdxlnmegu ougjqkoqkq (kdtwzlbwsq, bephfxvnxd - ktbsdgjwqy)
Phase 1
-
100
(IBI305)
hwlnujeonu(hcqqucsvxw) = gdckgqaipd awflaihpdr (jwxuiwpcxg, xghdlafypc - uhsnmdufbg)
-
04 Nov 2020
(Bevacizumab)
hwlnujeonu(hcqqucsvxw) = wdibdfcffq awflaihpdr (jwxuiwpcxg, fuhxszxfjg - vlwoxhdctx)
Not Applicable
50
ynopuyorbr(habqpjbhxe) = gngjnnkynf hnjrtgdmby (eahskocpvl, 41.3% - 77.9%)
-
19 Sep 2020
ynopuyorbr(habqpjbhxe) = rkwfxrrqan hnjrtgdmby (eahskocpvl, 52.8% - 91.5%)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free